We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ProBioGen and Lava Therapeutics Sign Development and Manufacturing Agreement for Novel Bispecific Molecule


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ProBioGen and Lava Therapeutics Sign Development and Manufacturing Agreement for Novel Bispecific Molecule"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen and Lava Therapeutics have announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.

Founded in 2016, Lava Therapeutics works on the development of antibody formats for the successful retrieval and activation of the body’s own immune system to effectively kill cancer cells in the tumor microenvironment. Under the agreement and using its CHO.RiGHT™ expression platform, including its recently launched DirectedLuck Transposase technology for generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format. With subsequent process development and GMP manufacturing, this project depicts another full-service program conducted at ProBioGen.


Advertisement